IXICO PLC (LSE:IXI, OTC:PHYOF) said on Thursday that it expects full-year revenues to come in ahead of expectations, marking a return to growth as the neuroscience imaging group builds momentum across its commercial strategy.
The company, which provides artificial intelligence-driven analytics to support drug development in neurological disorders, said revenues for the year ending 30 September are set to be at least £6.3 million.
This would represent a 9% increase on the previous year and the strongest annual performance since it shifted focus to its current growth strategy.
IXICO added that it expects revenue growth to continue into 2026, helping to push the business towards medium-term profitability. It is projecting a year-end cash balance of no less than £3 million.
Growth has been supported by the firm’s “Innovate Lead Scale” strategy, which combines scientific development with expansion into new geographies and therapeutic areas.
Increased investment in 2025 is expected to fuel further revenue gains in the coming year.
The update builds on guidance given in April, when the company reported a positive first-half trading performance.
CEO Bram Goorden said: "The Innovate Lead Scale strategy outlined during our capital raise has begun to deliver results.
"The positive momentum is a result of a team approach, executing with discipline to grow revenues, expand market share and diversify the neurological therapeutic areas we operate in.
"In addition, we are rapidly advancing our technology platform offering with new differentiated biomarker analytics products and applications fit for scale.
"This activity strengthens my belief that we will continue to build upon this year's commercial success and the progress we are making towards profitability in the medium term."